DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug ...

AstraZeneca (LSE:AZN) saw its share price decline by 3.5% in the last quarter, a period marked by several key developments, including the European approval of DATROWAY for breast cancer treatment and ...

First approval in the EU for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 trial showing 37% reduction in the risk of disease progression or death versus chemotherapy ...

Datroway (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with ...

DATROWAY ® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative ...

(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Tuesday said Datroway has secured EU approval to treat breast cancer patients. Daiichi Sankyo, a Tokyo-based pharmaceutical company, and ...

(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Tuesday said Datroway has secured EU approval to treat breast cancer patients. Daiichi Sankyo, a Tokyo-based pharmaceutical company ...